SI-BONE/SIBN

$14.97

-4.58%
-
1D1W1MYTD1YMAX

About SI-BONE

SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.

Ticker

SIBN

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Jeffrey Dunn

Employees

344

Headquarters

Santa clara, United States

SI-BONE Metrics

BasicAdvanced
$614.74M
Market cap
-
P/E ratio
-$1.13
EPS
1.23
Beta
-
Dividend rate
$614.74M
1.23149
$29.51
$14.88
423.83K
9.012
8.149
21.293
21.293
-22.34%
-32.38%
-25.24%
4.426
3.597
3.629
30.52%
36.79%
23.69%

What the Analysts think about SI-BONE

Analyst Ratings

Majority rating from 9 analysts.
Buy

Price Targets

Average projection from 9 analysts.
78.16% upside
High $32.00
Low $24.00
$14.97
Current price
$26.67
Average price target

SI-BONE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-28.09% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$38.8M
14.12%
Net income
$-10.9M
9%
Profit margin
-28.09%
-4.49%

SI-BONE Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 3.44%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.32
-$0.30
-$0.25
-$0.27
-
Expected
-$0.41
-$0.40
-$0.34
-$0.28
-$0.31
Surprise
-21.87%
-24.36%
-27.06%
-3.44%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for SI-BONE stock?

SI-BONE (SIBN) has a market cap of $614.74M as of April 14, 2024.

What is the P/E ratio for SI-BONE stock?

The price to earnings (P/E) ratio for SI-BONE (SIBN) stock is 0 as of April 14, 2024.

Does SI-BONE stock pay dividends?

No, SI-BONE (SIBN) stock does not pay dividends to its shareholders as of April 14, 2024.

When is the next SI-BONE dividend payment date?

SI-BONE (SIBN) stock does not pay dividends to its shareholders.

What is the beta indicator for SI-BONE?

SI-BONE (SIBN) has a beta rating of 1.23. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the SI-BONE stock price target?

The target price for SI-BONE (SIBN) stock is $26.67, which is 78.16% above the current price of $14.97. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell SI-BONE stock

Buy or sell SI-BONE stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing